C6D0 Stock Overview
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Allarity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.73 |
| 52 Week High | US$72.10 |
| 52 Week Low | US$1.73 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -15.67% |
| 1 Year Change | -97.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| C6D0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -1.2% |
| 1Y | -97.0% | -19.8% | 1.8% |
Return vs Industry: C6D0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: C6D0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| C6D0 volatility | |
|---|---|
| C6D0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C6D0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine C6D0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 13 | James Cullem | www.allarity.com |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Allarity Therapeutics, Inc. Fundamentals Summary
| C6D0 fundamental statistics | |
|---|---|
| Market cap | €3.16m |
| Earnings (TTM) | -€18.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs C6D0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C6D0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.76m |
| Earnings | -US$19.75m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -1,120.1% |
How did C6D0 perform over the long term?
See historical performance and comparison